Nima Farzan - 10 Feb 2023 Form 4/A - Amendment Insider Report for Kinnate Biopharma Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Mark A. Meltz, attorney in fact
Issuer symbol: N/A
Transactions as of: 10 Feb 2023
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 15 Feb 2023, 10:01:38 UTC
Date Of Original Report: 14 Feb 2023
Previous filing: 03 Jun 2022
Next filing: 08 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNTE	Employee Stock Option (right to buy)	Award	$0	+750,000		$0.000000	750,000	10 Feb 2023	Common Stock	750,000	$6.78	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date.

Content

One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date.